General
Preferred name
teniposide
Synonyms
NSC 122819 ()
VM26 ()
NSC 122819, VM-26 ()
Vumon ()
Teniposido ()
VM-26 ()
NSC-122819 ()
P&D ID
PD012680
CAS
29767-20-2
Tags
available
drug
Approved by
FDA
First approval
1992
Drug indication
Neoplasm
Acute lymphoblastic leukaemia
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
A podophyllotoxin derivative which achieves cytotoxicity by inhibiting type II topoisomerase activity. Many (85) isomeric alternatives for this compound are listed on PubChem. Click here to link directly to the PubChem listing. The structure shown here matches that shown in the INN document for this compound.
(GtoPdb)
PHARMACODYNAMICS
Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle. Teniposide prevents cell mitosis by causing single and double stranded DNA breaks as well as cross linking between protein and DNA.
DESCRIPTION
Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.
PRICE
45
DESCRIPTION
Potent PDGFRalpha and PDGFRbeta inhbitor; also inhibits c-Abl, Lck, c-Src and Fyn kinases
(Tocris Bioactive Compound Library)
DESCRIPTION
Teniposide (VM26), a semisynthetic derivative of podophyllotoxin with antitumor activity, inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
11
Organisms
0
Compound Sets
23
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
59
Molecular Weight
656.16
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
8
Aromatic Ring Count
3
cLogP
2.75
TPSA
160.83
Fraction CSP3
0.47
Chiral centers
10.0
Largest ring
6.0
QED
0.33
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Topo II
Topoisomerase
TOP2A, TOP2B
Primary Target
DNA Topoisomerase
MOA
Inhibitor
Topoisomerase inhibitor
Indication
acute lymphoblastic leukemia (ALL)
Therapeutic Class
Anticancer Agents
Pathway
Cell Cycle/DNA Damage
DNA Damage/DNA Repair
Source data

